R
Rod Junor
Researcher at Pfizer
Publications - 5
Citations - 119
Rod Junor is an academic researcher from Pfizer. The author has contributed to research in topics: Tanezumab & WOMAC. The author has an hindex of 2, co-authored 5 publications receiving 66 citations.
Papers
More filters
Journal ArticleDOI
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Francis Berenbaum,Francisco J. Blanco,Ali Guermazi,Kenji Miki,Takaharu Yamabe,Lars Viktrup,Rod Junor,William Carey,Mark T. Brown,Christine R. West,Kenneth M. Verburg +10 more
TL;DR: Tanezumab 5 mg statistically significantly improved pain, physical function and PGA-OA, but tanezumsumab 2.5mg only achieved two co-primary end points, but there was a statistically significant improvement in WOMAC Pain and Physical Function, but not PGA -OA.
Journal ArticleDOI
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
Francis Berenbaum,Richard M. Langford,Serge Perrot,Kenji Miki,Francisco J. Blanco,Takaharu Yamabe,Naoki Isogawa,Rod Junor,William Carey,Lars Viktrup,Christine R. West,Mark T. Brown,Kenneth M. Verburg +12 more
TL;DR: In this article, the authors evaluated if early improvements in pain and function with subcutaneous tanezumab are meaningful and sustained over 24-weeks, and found that the onset of efficacy of sub-cutaneous TANEZUMAB was within the first week, and efficacy was maintained through the 24-week treatment period.
Proceedings ArticleDOI
Lb0007 subcutaneous tanezumab for osteoarthritis pain: a 24-week phase 3 study with a 24-week follow up
Francis Berenbaum,Francisco J. Blanco,Ali Guermazi,Eric Vignon,Kenji Miki,Takaharu Yamabe,Lars Viktrup,Rod Junor,William Carey,Mark T. Brown,Ken Verburg,Christine R. West +11 more
TL;DR: Tanezumab 5 mg significantly improved all co-primary endpoints of pain, physical function, and PGA-OA and significantly improved pain and physical function in patients with moderate to severe OA pain who have not responded to or cannot tolerate standard of care opioids.
Journal ArticleDOI
Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks
Francis Berenbaum,R. Langford,Serge Perrot,K. Miki,Francisco J. Blanco,Takaharu Yamabe,Naoki Isogawa,S. Araki,Rod Junor,William Carey,Lars Viktrup,Christine R. West,Mark T. Brown,Kenneth M. Verburg +13 more
Journal ArticleDOI
Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera.
Francis Berenbaum,Francisco J. Blanco,Ali Guermazi,Kenji Miki,Takaharu Yamabe,Lars Viktrup,Rod Junor,William Carey,Mark T. Brown,Christine R. West,Kenneth M. Verburg +10 more
TL;DR: In this study, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale and Physical Function subscale were measured using an 11-point numeric rating scale and each subscale was summed and averaged to determine each mean subscale score.